Here, we observed that ponatinib is effective to ameliorate high-fat diet (HFD)-induced hyperlipidemia and NAFLD in leptin-deficient obesity mice model. The gene discussed is LEP; the disease is metabolic dysfunction-associated steatotic liver disease.